Lea Hildebrandt

Ms. Lea Hildebrandt

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2022 in Life
Verified
Journal Article
Open access
PDF file
LHLea Hildebrandt
Lea Hildebrandt
MDMaja-Theresa Dieterlen
Maja-Theresa Dieterlen
KKKristin Klaeske
Kristin Klaeske
JHJosephina Haunschild
Josephina Haunschild
DSDiyar Saeed
Diyar Saeed
KJKhalil Jawad
Khalil Jawad
Disturbances in the ubiquitin proteasome system, and especially changes of the E3 ligases, are subjects of interest when searching for causes and therapies for cardiomyopathies. The aim of this study was to clarify whether the myostatin/AKT/forkhead box O (FOXO) pathway, which regulates the expression of the E3 ligases muscle atrophy F-box gene (MAFbx) and muscle ring-finger protein-1 (MuRF1), is changed in dilated cardiomyopathy of ischemic origin (IDCM) and dilated cardiomyopathy of non-ischemic origin (NIDCM). The mRNA and protein expression of myostatin, AKT, FOXO1, FOXO3, MAFbx and MuRF1 were quantified by real-time polymerase chain reaction and ELISA, respectively, in myocardial tissue from 26 IDCM and 23 NIDCM patients. Septal tissue from 17 patients undergoing Morrow resection served as a control. MAFbx and FOXO1 mRNA and protein expression (all p < 0.05), AKT mRNA (p < 0.01) and myostatin protein expression (p = 0.02) were decreased in NIDCM patients compared to the control group. Apart from decreases of AKT and MAFbx mRNA expression (both p < 0.01), no significant differences were detected in IDCM patients compared to the control group. Our results demonstrate that the myostatin/AKT/FOXO pathway is altered in NIDCM but not in IDCM patients. FOXO1 seems to be an important drug target for regulating the expression of MAFbx in NIDCM patients.

11 May 2023 in Obesity Facts
Verified
Journal Article
Open access
PDF file
EMEva Katharina Messer
Eva Katharina Messer
AMAnna Lassia Meyer
Anna Lassia Meyer
KKKristin Klaeske
Kristin Klaeske
FSFranz Sieg
Franz Sieg
SESandra Eifert
Sandra Eifert
MDMaja-Theresa Dieterlen
Maja-Theresa Dieterlen
Introduction: Infections are a major problem after left ventricular assist device (LVAD) implantation that affects morbidity, mortality, and the quality of life. Obesity often increases the risk for infection. In the cohort of LVAD patients, it is unknown if obesity affects the immunological parameters involved in viral defense. Therefore, this study investigated whether overweight or obesity affects immunological parameters such as CD8+ T cells and natural killer (NK) cells. Methods: Immune cell subsets of CD8+ T cells and NK cells were compared between normal-weight (BMI 18.5–24.9 kg/m2, n = 17), pre-obese (BMI 25.0–29.9 kg/m2, n = 24), and obese (BMI ≥30 kg/m2, n = 27) patients. Cell subsets and cytokine serum levels were quantified prior to LVAD implantation and at 3, 6, and 12 months after LVAD implantation. Results: At the end of the first postoperative year, obese patients (31.8% ± 2.1%) had a lower proportion of CD8+ T cells than normal-weight patients (42.4% ± 4.1%; p = 0.04), and the percentage of CD8+ T cells was negatively correlated with BMI (p = 0.03; r = −0.329). The proportion of circulating NK cells increased after LVAD implantation patients in normal-weight (p = 0.01) and obese patients (p < 0.01). Patients with pre-obesity showed a delayed increase (p < 0.01) 12 months after LVAD implantation. Further, obese patients showed an increase in the percentage of CD57+ NK cells after 6 and 12 months (p = 0.01) of treatment, higher proportions of CD56bright NK cells (p = 0.01), and lower proportions of CD56dim/neg NK cells (p = 0.03) 3 months after LVAD implantation than normal-weight patients. The proportion of CD56bright NK cells positively correlated with BMI (p < 0.01, r = 0.403) 1 year after LVAD implantation. Conclusions: This study documented that obesity affects CD8+ T cells and subsets of NK cells in patients with LVAD in the first year after LVAD implantation. Lower proportions of CD8+ T cells and CD56dim/neg NK cells and higher proportion of CD56bright NK cells were detected in obese but not in pre-obese and normal-weight LVAD patients during the first year after LVAD implantation. The induced immunological imbalance and phenotypic changes of T and NK cells may influence viral and bacterial immunoreactivity.

20 June 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
MDMaja-Theresa Dieterlen
Maja-Theresa Dieterlen
LHLea Hildebrandt
Lea Hildebrandt
KKKristin Klaeske
Kristin Klaeske
JJJoanna Jozwiak-Nozdrzykowska
Joanna Jozwiak-Nozdrzykowska
MBMichael Borger
Michael Borger
MNMichal Nozdrzykowski
Michal Nozdrzykowski
Introduction: The implantation of a left ventricular assist device (LVAD) is a life-saving therapeutic option for patients with advanced heart failure. The treatment goal has to be determined prior to LVAD implantation. However, prognostic evaluation for defining the treatment goal could be improved for a time- and cost-effective medical treatment. Methods: Our study comprised seven patients who were weaned from LVAD (recovery group) and a control group without weaning (non-recovery group; n = 7). Myocardial tissue was analysed for connective tissue content by Masson–Goldner trichrome staining and for collagen I and collagen III expression by quantitative real-time PCR and immunohistochemistry. Results: The histological evaluation revealed comparable values for the percentage of total connective tissue (non-recovery: 46.3% [95% CI: 15.9–76.7], recovery: 43.4% [95% CI: 13.7–73.2], p = 0.43). mRNA expression analysis for collagen I and III expression could not detect a difference in collagen I (p = 0.16) and collagen III expression (p = 0.12) between the non-recovery and the recovery group. Immunohistochemical staining revealed that the percentages of collagen I (p = 0.05) and of collagen III (p = 0.01) were reduced in patients who do not recover compared to patients who recover under LVAD support. Conclusions: Our data indicate that histological evaluation for collagen expression prior to LVAD implantation could detect differences in the collagen content that could be helpful for estimating the weaning success.